Onconetix, INC DEF 14A proxy statements

Onconetix calls an April 30, 2026 special meeting to authorize one or more reverse stock splits to support Nasdaq compliance, with an aggregate limit of 1-for-100 and a one-year execution window.

Onconetix, Inc. is calling a special meeting of stockholders to vote on a reverse stock split proposal aimed at maintaining its Nasdaq listing and improving stock marketability.

Onconetix, Inc. calls for its Annual Meeting to approve significant private placement financings, elect new directors, and ratify its independent auditor.

Onconetix is seeking stockholder approval for a reverse stock split to increase its stock price and regain compliance with Nasdaq listing requirements.

Onconetix, Inc. has entered into agreements for a $2 million private placement (PIPE) and a committed equity facility (ELOC) to bolster its working capital.

Onconetix is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq listing requirements after receiving notices regarding minimum bid price and stockholders' equity.

Onconetix is seeking stockholder approval for several proposals at its upcoming annual meeting, including the election of directors, an amendment to its equity incentive plan, and a reverse stock split.